To date, the management of patients with suspected or confirmed Ebolavirus 
disease (EVD) depends on quarantine, symptomatic management and supportive care, 
as there are no approved vaccines or treatments available for human use. 
However, accelerated by the recent large outbreak in West Africa, significant 
progress has been made towards vaccine development but also towards specific 
treatment with convalescent plasma and monoclonal antibodies. Areas covered: We 
describe recent developments in monoclonal antibody treatment for EVD, 
encompassing mAb114 and the MB-003, ZMAb, ZMapp™ and MIL-77E cocktails. Expert 
opinion: Preventive measures, are, and will remain essential to curb EVD 
outbreaks; even more so with vaccine development progressing. However, research 
for treatment options must not be neglected. Small-scale animal and individual 
human case studies show that monoclonal antibodies (mAbs) can be effective for 
EVD treatment; thus justifying exploration in clinical trials. Potential 
limitations are that high doses may be needed to yield clinical efficacy; 
epitope mutations might reduce efficacy; and constant evolution of 
(outbreak-specific) mAb mixtures might be required. Interim advice based on the 
clinical experience to date is that treatment of patients with mAbs is sensible, 
provided those could be made available in the necessary amounts in time.